Evaluation of Clinical, Pathological, and Treatment Effects on Prognosis in Non-Metastatic Esophagus Squamous Cell Carcinoma


Creative Commons License

Dikici H. Z., ÖZDEMİR N., Karaahmetoglu S. O.

EUROPEAN JOURNAL OF THERAPEUTICS, cilt.32, sa.3, ss.290-301, 2026 (ESCI, TRDizin)

Özet

Objective: This study analyzed demographic, clinical, and pathological features, treatment responses, and survival outcomes in non-metastatic esophageal SCC patients. Methods: A retrospective review of 74 patients was conducted. Performance status was assessed using ECOG, treatment response via RECIST 1.1, and staging via AJCC 7th edition TNM. Results: The male-to-female ratio was 0.95, with a mean age of 50.6. Tumors were mainly distal (58%), and most patients (68.7%) presented at stage 2 (25%) or 3 (43.7%). Surgery was performed in 64.9% (47.3% surgery only, 35.1% CRT only, 17.6% CRT + surgery). Median overall and disease-free survival were 38 and 24 months, respectively. Female gender, middle/lower tumor location, fewer metastatic lymph nodes, and CRT + surgery correlated with better survival (p < 0.05). Conclusion: Surgery was the most common treatment, but CRT + surgery yielded superior survival. Local recurrence was more frequent than distant metastasis. A combined approach is crucial for optimal outcomes.